New Weight-Loss drug UBT251 enters Mid-Stage trial
NCT ID NCT07395687
First seen Feb 14, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This study tests whether UBT251 is safe and effective for people who are overweight or have obesity. About 333 participants will receive either UBT251 or a placebo injection. The main goals are to check for side effects and measure weight change over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Company, Inc
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
-
Altasciences Clinical Kansas, Inc.
RECRUITINGOverland Park, Kansas, 66212, United States
-
Altasciences Clinical LA, Inc.
RECRUITINGCypress, California, 90630, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251
What this could lead to
If it works, this could lead to a new weight-loss medication that helps people with overweight or obesity lose weight safely.
What could go wrong
This is an early Phase 2 trial, so the drug may not prove effective or could have side effects. Results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.